Skip to content
Veracyte is a leading genomic diagnostics company that is fundamentally improving patient care by resolving diagnostic uncertainty with evidence that is trustworthy and actionable. The company’s products uniquely combine genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward without risky, costly surgery that is often unnecessary.
Since its founding in 2008, Veracyte has commercialized three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis and collectively target a $2 billion market opportunity. Veracyte is based in South San Francisco, California. Veracyte’s common stock is listed on The NASDAQ Global Market under the symbol VCYT.


Press Releases

Date Title and Summary Additional Formats
Toggle Summary Veracyte Announces New Data That Advance Understanding of Genomic Alterations Targeted by Precision Medicine Therapies for Thyroid Cancer
Findings Presented at 89 th Annual Meeting of the American Thyroid Association SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 2, 2019-- Veracyte, Inc . (Nasdaq: VCYT) today announced new data that advance understanding of the frequency, positive predictive value and co-occurrence of genomic
Toggle Summary Veracyte Announces New Data Characterizing Genomic Alterations in Thyroid Cancer To Be Presented at 89th Annual Meeting of the American Thyroid Association
Findings derived from Afirma Xpression Atlas analysis of company’s extensive biorepository of thyroid nodule fine needle aspiration samples SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 30, 2019-- Veracyte, Inc . (Nasdaq: VCYT) announced today that new data advancing the understanding of


There are currently no events to display.


Title Documents

Corporate Presentation October 2019